Therapy of multiple myeloma. What is confirmed?

被引:0
作者
Peest, D. [1 ]
Ganser, A. [1 ]
Einsele, H. [2 ]
机构
[1] Hannover Med Sch, Klin Hamatol Hamostaseol Onkol & Stammzelltranspl, D-30625 Hannover, Germany
[2] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
来源
INTERNIST | 2013年 / 54卷 / 12期
关键词
Multiple myeloma; Smoldering multiple myeloma; Stem cell transplantation; Proteasome inhibitors; Immunomodulatory drugs; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; MONOCLONAL GAMMOPATHY; LONG-TERM; MAINTENANCE THERAPY; ELDERLY-PATIENTS; IMWG CONSENSUS; MELPHALAN; PREDNISONE; SURVIVAL;
D O I
10.1007/s00108-013-3323-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma (MM) is a malignant plasma cell disorder with clonal development. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are precursor stages of MM and both have to be differentiated from MM which is characterized by organ complications. High-dose chemotherapy combined with autologous stem cell support is the therapy of choice for most patients in order to achieve long-lasting complete remission with few symptoms, prevention of new organ complications and survival prolongation. Patients who cannot be intensively treated due to advanced age and comorbidities should be treated with low-dose chemotherapy, normally alkylating agents, for improved quality of life and also survival prolongation. Including thalidomide, lenalidomide, pomalidomide, bortezomib or carfilzomib in both high-dose and low-dose chemotherapy concepts results in a significantly higher remission rate and longer survival. Allogeneic stem cell transplantation is associated with a relatively high mortality during the first year after transplantation which will be refined with the aim of healing in various trials and is an alternative treatment approach for selected patients. A treatment concept for MM patients has to be individually complemented by local irradiation, administration of bisphosphonates and supportive infusions of immunoglobulins.
引用
收藏
页码:1434 / +
页数:7
相关论文
共 30 条
[1]  
[Anonymous], 2013, SEER Cancer Statistics Review, 1975-2010
[2]   Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment [J].
Armeson, K. E. ;
Hill, E. G. ;
Costa, L. J. .
BONE MARROW TRANSPLANTATION, 2013, 48 (04) :562-567
[3]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[4]   Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms [J].
Barlogie, Bart ;
Anaissie, Elias ;
van Rhee, Frits ;
Shaughnessy, John D., Jr. ;
Szymonifka, Jackie ;
Hoering, Antje ;
Petty, Nathan ;
Crowley, John .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) :3023-3027
[5]   Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation [J].
Bjorkstrand, B ;
Ljungman, P ;
Svensson, H ;
Hermans, J ;
Alegre, A ;
Apperley, J ;
Blade, J ;
Carlson, K ;
Cavo, M ;
Ferrant, A ;
Goldstone, AH ;
deLaurenzi, A ;
Majolino, I ;
Marcus, R ;
Prentice, HG ;
Remes, K ;
Samson, D ;
Sureda, A ;
Verdonck, LF ;
Volin, L ;
Gahrton, G .
BLOOD, 1996, 88 (12) :4711-4718
[6]   High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].
Child, JA ;
Morgan, GJ ;
Davies, FE ;
Owen, RG ;
Bell, SE ;
Hawkins, K ;
Brown, J ;
Drayson, MT ;
Selby, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883
[7]   Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells [J].
Corradini, P ;
Voena, C ;
Tarella, C ;
Astolfi, M ;
Ladetto, M ;
Palumbo, A ;
Van Lint, MT ;
Bacigalupo, A ;
Santoro, A ;
Musso, M ;
Majolino, I ;
Boccadoro, M ;
Pileri, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :208-215
[8]   Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma [J].
Dudeney, S ;
Lieberman, IH ;
Reinhardt, MK ;
Hussein, M .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2382-2387
[9]   Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial [J].
Facon, Thierry ;
Mary, Jean Yves ;
Hulin, Cyrille ;
Benbouker, Lofti ;
Attal, Michel ;
Pegourie, Brigitte ;
Renaud, Marc ;
Guillerm, Jean Luc Harousseau Gaelle ;
Ahletaix, Carine ;
Dib, Mamoun ;
Voillat, Laurent ;
Maisonneuve, Herve ;
Troncy, Jacques ;
Dervaux, Weronique ;
Monconduit, Mathieu ;
Martin, Claude ;
Casassus, Philippe ;
Jaubert, Jerome ;
Jardel, Henry ;
Doyen, Chantal ;
Kolb, Brigitte ;
Anglaret, Bruno ;
Grosbois, Bernard ;
Yakoub-Agha, Ibrahim ;
Mathiot, Claire ;
Avet-Loiseau, Herve .
LANCET, 2007, 370 (9594) :1209-1218
[10]   Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study [J].
Gahrton, Gosta ;
Iacobelli, Simona ;
Bjorkstrand, Bo ;
Hegenbart, Ute ;
Gruber, Astrid ;
Greinix, Hildegard ;
Volin, Liisa ;
Narni, Franco ;
Carella, Angelo Michele ;
Beksac, Meral ;
Bosi, Alberto ;
Milone, Giuseppe ;
Corradini, Paolo ;
Schoenland, Stefan ;
Friberg, Kristina ;
van Biezen, Anja ;
Goldschmidt, Hartmut ;
de Witte, Theo ;
Morris, Curly ;
Niederwieser, Dietger ;
Garderet, Laurent ;
Kroeger, Nicolaus .
BLOOD, 2013, 121 (25) :5055-5063